After the Unified Patent Court’s Munich Local Division announced a multi-country preliminary injunction against NanoString’s (NSTG) CosMx Spatial Molecular Imager in a patent fight victory for 10x Genomics (TXG), Canaccord analyst Kyle Mikson noted that today’s order relates to the 782 patent and that the UPC will issue a preliminary injunction decision related to the 928 patent on October 10. The analyst, who also noted that NanoString said it will immediately appeal the preliminary injunction, sees “multiple reasons why there may not be clear readthroughs to U.S. litigation.” The firm reiterates Buy ratings on NanoString and 10x Genomics and maintains its price targets at $10 and $70, respectively.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on TXG:
- NanoString says will ‘immediately appeal’ preliminary injunction in EU
- 10x Genomics surpasses 100 Xenium Analyzer shipments in eight months
- 10x Genomics price target raised to $70 from $65 at Canaccord
- 10x Genomics price target raised to $70 from $66 at TD Cowen
- 10x Genomics price target raised to $75 from $65 at Citi